On the evolutionary epidemiology of SARS-CoV-2.


Journal

Current biology : CB
ISSN: 1879-0445
Titre abrégé: Curr Biol
Pays: England
ID NLM: 9107782

Informations de publication

Date de publication:
03 08 2020
Historique:
entrez: 5 8 2020
pubmed: 5 8 2020
medline: 14 8 2020
Statut: ppublish

Résumé

There is no doubt that the novel coronavirus SARS-CoV-2 that causes COVID-19 is mutating and thus has the potential to adapt during the current pandemic. Whether this evolution will lead to changes in the transmission, the duration, or the severity of the disease is not clear. This has led to considerable scientific and media debate, from raising alarms about evolutionary change to dismissing it. Here we review what little is currently known about the evolution of SARS-CoV-2 and extend existing evolutionary theory to consider how selection might be acting upon the virus during the COVID-19 pandemic. Although there is currently no definitive evidence that SARS-CoV-2 is undergoing further adaptation, continued evidence-based analysis of evolutionary change is important so that public health measures can be adjusted in response to substantive changes in the infectivity or severity of COVID-19.

Identifiants

pubmed: 32750338
pii: S0960-9822(20)30847-2
doi: 10.1016/j.cub.2020.06.031
pmc: PMC7287426
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

R849-R857

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Nat Rev Genet. 2018 Dec;19(12):756-769
pubmed: 30305704
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
PLoS Pathog. 2015 Apr 21;11(4):e1004810
pubmed: 25898324
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Lancet Infect Dis. 2020 May;20(5):553-558
pubmed: 32171059
PLoS Pathog. 2013 Mar;9(3):e1003209
pubmed: 23516359
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Emerg Infect Dis. 2006 Nov;12(11):1657-62
pubmed: 17283614
Nat Med. 2019 Feb;25(2):212-220
pubmed: 30692696
Sci Rep. 2018 Oct 11;8(1):15177
pubmed: 30310104
Q Rev Biol. 1996 Mar;71(1):37-78
pubmed: 8919665
Genetics. 1998 Mar;148(3):929-36
pubmed: 9539414
Nature. 2008 Feb 21;451(7181):990-3
pubmed: 18288193
Elife. 2019 Aug 15;8:
pubmed: 31411558
Trends Ecol Evol. 2016 Oct;31(10):776-788
pubmed: 27567404
J Theor Biol. 1994 Aug 7;169(3):253-65
pubmed: 7967617
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Am Nat. 2004 Apr;163(4):E40-63
pubmed: 15122509
Science. 2004 Mar 12;303(5664):1666-9
pubmed: 14752165
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Nat Microbiol. 2020 Jul 28;:
pubmed: 32724171
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
J Evol Biol. 2018 Mar;31(3):382-392
pubmed: 29288541
Ecol Lett. 2007 Oct;10(10):876-88
pubmed: 17845288
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Parasitology. 2016 Jun;143(7):915-930
pubmed: 26302775

Auteurs

Troy Day (T)

Department of Mathematics and Statistics, Department of Biology, Queen's University, Kingston, ON K7L 3N6, Canada. Electronic address: day@queensu.ca.

Sylvain Gandon (S)

CEFE, CNRS, University of Montpellier, Paul Valéry University of Montpellier, EPHE, IRD, 34293 Montpellier Cedex 5, France. Electronic address: sylvain.gandon@cefe.cnrs.fr.

Sébastien Lion (S)

CEFE, CNRS, University of Montpellier, Paul Valéry University of Montpellier, EPHE, IRD, 34293 Montpellier Cedex 5, France. Electronic address: sebastien.lion@cefe.cnrs.fr.

Sarah P Otto (SP)

Department of Zoology and Biodiversity Research Centre, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. Electronic address: otto@zoology.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH